About Brii Biosciences
Brii Biosciences is a company based in San Francisco (United States) founded in 2018 by Zhi Hong. Brii Biosciences has raised $415 million across 3 funding rounds from investors including Arch Venture Partners, Invesco and Lake Bleu Capital. The company has 98 employees as of December 31, 2024. Brii Biosciences operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter San Francisco, United States
- Employees 98 as on 31 Dec, 2024
- Founders Zhi Hong
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Brii Biosciences Limited
-
Annual Revenue
Not available
-
Net Profit
-$70.94 M (USD)-185.2as on Dec 31, 2024
-
EBITDA
-$62.11 M (USD)25.29as on Dec 31, 2024
-
Total Equity Funding
$415 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Post-IPO
Sep 07, 2021
-
Investors
Arch Venture Partners
& 8 more
-
Employee Count
98
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Brii Biosciences
Brii Biosciences is a publicly listed company on the HKEX with ticker symbol 2137 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Brii Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Brii Biosciences
Brii Biosciences has successfully raised a total of $415M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Brii Biosciences
Brii Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Arch Venture Partners, Invesco and Lake Bleu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Locked | Locked | Locked | |
|
Private equity investments are managed by Yunfeng Capital in China.
|
Locked | Locked | Locked |
Investor details for Brii Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Brii Biosciences
Investment portfolio details for Brii Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Brii Biosciences
Detailed financials for Brii Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Brii Biosciences Comparisons
Peer comparison for Brii Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Brii Biosciences
Brii Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Brii Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Brii Biosciences
Complete news archive for Brii Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brii Biosciences
Brii Biosciences was founded in 2018.
Brii Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Zhi Hong is the current CEO of Brii Biosciences. They have also founded this company.
Brii Biosciences is a funded company, having raised a total of $415M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Brii Biosciences is 98.
Developer of biologics to treat hepatitis B infection. It has clinical programs focused on hepatitis B virus (HBV) infection and immunotherapeutics to treat infectious diseases. It has licensed rights to develop a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in China. It is also developing VIR-2218, an investigational RNA interference (RNAi) therapeutics to treat hepatitis B infection (licensed from Vir Biotechnology).
Brii Biosciences's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Yes, Brii Biosciences is publicly traded on HKEX under the ticker symbol 2137.
Brii Biosciences has 9 investors. Key investors include Arch Venture Partners, Invesco, Lake Bleu Capital, GIC, and Yunfeng Capital.
The ticker symbol of Brii Biosciences is 2137 on HKEX.